Literature DB >> 3116917

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.

J Blaser1, B B Stone, M C Groner, S H Zinner.   

Abstract

An in vitro pharmacokinetic model was used to study the comparative antibacterial activities of multiple-dose regimens of enoxacin and netilmicin. Strains of Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, and Staphylococcus aureus were exposed to changing drug concentrations, mimicking human two-compartment pharmacokinetics. Oral administration was simulated for the quinolone, and intravenous administration was simulated for the aminoglycoside. Similar ratios of peak concentration to MIC resulted in similar changes in bacterial concentrations over time with both compounds. Following the initial dose, a rapid bactericidal effect occurred, with a greater than 99% reduction of the bacterial counts within 4 h at peak concentrations more than three times the MIC. However, bacterial regrowth occurred within 24 h unless the peak concentration/MIC ratio exceeded 8:1 (P less than 0.01). For the regrowing bacteria, MICs were four- to eightfold higher, and little or no bactericidal effect occurred following the second and subsequent doses. These data demonstrate the equally potent bactericidal activity of orally administered enoxacin and intravenously administered netilmicin. Selection of resistant subpopulations was similar with each drug. The peak concentration/MIC ratio may be an important parameter in the clinical use of quinolone and aminoglycoside antibiotics.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3116917      PMCID: PMC174871          DOI: 10.1128/AAC.31.7.1054

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Two compartment kinetic model with multiple artificial capillary units.

Authors:  J Blaser; B B Stone; S H Zinner
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

2.  Determination of a new antibacterial agent (AT-2266) and its metabolites in plasma and urine by high-performance liquid chromatography.

Authors:  R Nakamura; T Yamaguchi; Y Sekine; M Hashimoto
Journal:  J Chromatogr       Date:  1983-12-09

3.  Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.

Authors:  C C Sanders; W E Sanders; R V Goering; V Werner
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

4.  Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model.

Authors:  A U Gerber; A P Vastola; J Brandel; W A Craig
Journal:  J Infect Dis       Date:  1982-11       Impact factor: 5.226

5.  Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model.

Authors:  J Blaser; B B Stone; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

6.  Impact of netilmicin regimens on the activities of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model.

Authors:  J Blaser; B B Stone; M C Groner; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

7.  Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes.

Authors:  P J McDonald; B L Wetherall; H Pruul
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

8.  Pharmacokinetics and tissue penetration of enoxacin.

Authors:  R Wise; R Lockley; J Dent; M Webberly
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

9.  In vitro models for the study of combination antibiotic therapy in neutropenic patients.

Authors:  S H Zinner; M Dudley; J Blaser
Journal:  Am J Med       Date:  1986-06-30       Impact factor: 4.965

10.  Influence of medium and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacin.

Authors:  J Blaser; M N Dudley; D Gilbert; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

View more
  134 in total

1.  Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

Authors:  J M Blondeau; X Zhao; G Hansen; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Use of Modeling Techniques to Aid in Antibiotic Selection.

Authors:  Alexander A. Firsov; Stephen H. Zinner
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

Review 3.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

Review 4.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

5.  Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis.

Authors:  M A Zeitlinger; P Dehghanyar; B X Mayer; B S Schenk; U Neckel; G Heinz; A Georgopoulos; M Müller; C Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

6.  Extended Interval Tobramycin Pharmacokinetics in a Pediatric Patient With Primary Ciliary Dyskinesia Presenting With an Acute Respiratory Exacerbation.

Authors:  Kristi L Higgins; Cady Noda; Jeremy S Stultz
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

7.  Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin.

Authors:  Robyn Defife; Marc H Scheetz; Joe M Feinglass; Michael J Postelnick; Kimberly K Scarsi
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 8.  Once-daily aminoglycoside administration: new strategies for an old drug.

Authors:  J M Kovarik; I M Hoepelman; J Verhoef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-09       Impact factor: 3.267

9.  Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; J C Vink-van den Berg; B M Michel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

10.  Antipseudomonal activity of simulated infusions of gentamicin alone or with piperacillin assessed by serum bactericidal rate and area under the killing curve.

Authors:  J E Tisdale; M T Pasko; J M Mylotte
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.